11
Views
3
CrossRef citations to date
0
Altmetric
Research Article

Challenges in Increasing Access to Buprenorphine Treatment for Opiate Addiction

, Ph.D., M.P.P., , M.D., , Ph.D., , Ph.D., , M.D., , M.A., , M.D., , Ph.D. & , M.D., M.PH. show all
Pages S8-S16 | Published online: 10 Jul 2009

References

  • McCormack L, Garfinkel S, Schnaier JL, Sangl J.. Consumer information development and use. Health Care Financing Review. 1996; 181: 15–29
  • Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE.. A placebo-controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend. 1995; 40: 17–25. [PUBMED], [INFOTRIEVE], [CROSSREF]
  • Mello NK, Mendelson JH, Kuehnle JC.. Buprenorphine effects on human heroin self-administration: an operant analysis. J Pharmacol Exp Ther. 1981; 223: 30–39
  • Johnson RE, Jaffe JH, Fudala PJ.. A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 1992; 267: 2750–2755. [PUBMED], [INFOTRIEVE], [CROSSREF]
  • Ling W, Wesson DR, Charuvastra C, Klett CJ.. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry. 1996; 53: 401–407. [PUBMED], [INFOTRIEVE]
  • Brooner RK, King VL, Kidorf M, Schmidt CW, Jr., Bigelow GE.. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry. 1997; 54: 71–80. [PUBMED], [INFOTRIEVE]
  • National Institute on Drug Abuse (NIDA).. Research Report Series—Heroin Abuse and Addiction, NIH Publication No. 00-4165.. Rockville, Md, NIDA. 1997
  • Shah B, Barnwell B, Bieler G. SUDAAN User's Manual Release 7.0. Research Triangle Park, NC, Research Triangle Institute. 1996
  • Scully JH, Wilk JE.. Selected characteristics and data of psychiatrists in the United States, 2001–2002. Academic Psychiatry. 2003; 27: 247–251. [PUBMED], [INFOTRIEVE], [CROSSREF]
  • Berwick DM.. Disseminating innovations in health care. JAMA. 2003; 89. 1969–1975
  • SAMHSA. Physician locator statistics July 2003. Available at:. www.buprenorphine.samhsa.gov
  • Auriacombe M, Franques P, Bertorelle V, Tignol J.. Use of buprenorphine for substitution treatment: a French experience in Bordeaux and Bayonne. Res Clin Forum. 1997; 19: 47–50
  • Auriacombe M, Tignol J.. Buprenorphine use in France: quality of life and conditions for treatment success. Res Clin Forum. 1997; 19: 25–32
  • Auriacombe M.. Overview of substitution treatment for heroin users in France. Farrell M, Howes S, Verster A, Davoli M. Reviewing Current Practice in Drug Substitution Treatment in Europe. , LisbonPortugal, EMCDDA. 1999; 61–68
  • Montoya ID, Herbeck DM, Svikis DS, Fitek DJ, Marcus SC, Pincus HA. Demographic and practice characteristics of psychiatrists who primarily treat patients with substance use disorders. Am J Addict. 2003; 12: 181–192. [PUBMED], [INFOTRIEVE]
  • National Association of State Mental Health Program Directors and National Association of State Alcohol and Drug Abuse Directors. National Dialogue on Co-occurring Mental Health and Substance Abuse Disorders. Alexandria, VA and Washington, DC: NASMHPD/NASADAD;. 1999
  • Rogers EM. Diffusion of innovations, Fourth edition., New York, Free Press. 1995
  • Ryan B, Gross N. The diffusion of hybrid seed corn in two Iowa communities. Rural Sociology. 1943; 8(1)15–24
  • Beal GM, Bohlen JM. How farm people accept new ideas. , AmesIowa, Cooperative Extension Service Report 15. 1955

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.